Trial Profile
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Glioma; Neurofibroma; Neurofibromatosis 1
- Focus Therapeutic Use
- 28 Jul 2023 Planned End Date changed from 22 Jun 2023 to 24 Jul 2024.
- 28 Jul 2023 Planned End Date changed from 22 Jun 2023 to 24 Jul 2024.
- 15 Jan 2022 Planned End Date changed from 31 Dec 2021 to 22 Jun 2023.